Australia's most trusted
source of pharma news
Monday, 16 September 2024
Posted 8 August 2024 AM
Major Australian pharmas are in the crosshairs of a potential class action lawsuit aiming to replicate a legal success in the US.
Shine Lawyers is investigating the link between proton pump inhibitor (PPI) drugs used to treat heartburn and reflux and adverse health impacts including stomach cancers and kidney failure.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.